Current Status of Cell Therapies in Stroke

Abstract

Stroke is a leading cause of death and disability in adults. Recovery after stroke is usually limited as there is no definite therapy to restore lost brain function. Cell therapy is an emerging paradigm in stroke therapy for patients with fixed neurologic deficits. Cell therapy for stroke may be greatly different from cell therapy for other disease conditions; the complexity of central nervous system structures and functions may limit its effectiveness. Recently, there have been several clinical trials of cell therapy for patients with ischemic stroke. In this review, the current status and limitations of cell therapy for stroke will be discussed. In addition, recent efforts and perspectives to improve therapeutic efficacy and safety of cell therapy will be summarized.

Stem-cell therapy for neurologic diseases

“…Epidural injection of autologous bone marrow derived mononuclear cells may provide environmental enrichment and help the detethered nerve roots to regenerate Stroke [49][50][51][52][53][54][55] Sudden onset of neurological deficits Spinal cord injury [56,57] Neurological deficits following trauma Perinatal brain injury [62,63] Neurological deficits following hypoxic trauma during and after birth…”

Intraventricular CXCL12 is neuroprotective and increases neurogenesis in a murine model of stroke

“…Although thrombolytic therapy and neuroendovascular intervention represents an advance for the treatment of acute stroke a large proportion of survivors still struggle with severe disabilities due to the limited time window for these therapies and frequent unsuccessful recanalization (Nakagomi et al 2015). There is no definitive therapy that can restore lost brain function (Bang 2009). Numerous approaches have been developed to protect the brain from ischemic damage but have limited success in clinical practice (Bang 2009).…”

“…There is no definitive therapy that can restore lost brain function (Bang 2009). Numerous approaches have been developed to protect the brain from ischemic damage but have limited success in clinical practice (Bang 2009).…”